(ONCE) - Earnings & Price History

ONCE: - 83.69, $2.62B, 1.82 (2.22%)

Sector: Healthcare - Industry: Biotechnology

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company develops SPK-RPE65, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It is also developing SPK-FIX program for hemophilia B; SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of a form of Batten disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and SPK-LHON for treating Leber hereditary optic neuropathy, as well as preclinical programs in development for the treatment of Huntington's disease and other neurodegenerative diseases. The company

Past ONCE reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-02-22BMO-1.1261.3864.7162.7659.5364.7-3.01%-2.20%-5.15%668.00K
2016-11-03BMO-1.0140.5146.9646.535.0746.5-0.98%▲-12.88%-13.74%2.51M
2016-08-10BMO-0.9758.4959.2558.9656.1260.24-0.49%-0.80%-1.28%448.47K
2016-05-04BMO-0.8432.2935.353531.735.3-0.99%-7.74%-8.66%501.12K
2016-03-09BMO-0.7331.960232.0332.9931.1133.853.00%-3.12%-0.22%389.35K
2015-11-04-0.4857.8260.0359.4356.359.68-1.00%▲-2.71%-3.68%393.60K

Login | Register
Tuesday Oct 24, 2017   EST
Enter a Ticker:

Economic Calendar

Chicago Fed National Activity Index 8:30 AM ET 4-Week Bill Announcement 11:00 AM ET 3-Month Bill Auction 11:30 AM ET 6-Month Bill Auction 11:30 AM ET 

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY256.11-1.00-0.39%63,840,997

Upgrades/Downgrades